In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs).
From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer.
If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectives
© 2026 The Perspective Bureau LLC. All rights reserved.
